key: cord-0014937-6gg5i80p
authors: Cai, Yingyun; Yu, Shuiqing; Chi, Xiaoli; Radoshitzky, Sheli R.; Kuhn, Jens H.; Berger, Edward A.
title: An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells
date: 2021-01-07
journal: PLoS One
DOI: 10.1371/journal.pone.0245024
sha: 37156d7a9f40cd159c9f3ff9a2d29ff810e69527
doc_id: 14937
cord_uid: 6gg5i80p

Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved. We designed an immunotoxin in which a single-chain variable region fragment of the EBOV glycoprotein-specific monoclonal antibody 6D8 was fused to the effector domains of Pseudomonas aeruginosa exotoxin A (PE38). This immunotoxin, 6D8-PE38, bound specifically to cells expressing EBOV glycoproteins. Importantly, 6D8-PE38 targeted EBOV-infected cells, as evidenced by inhibition of infectious EBOV production from infected cells, including primary human macrophages. The data presented here provide a proof of concept for immunotoxin-based targeted killing of infected cells as a potential antiviral intervention for Ebola virus disease.

Ebola virus (EBOV; Mononegavirales: Filoviridae: Ebolavirus) causes Ebola virus disease (EVD), a severe human disease associated with lethality. There have been at least 19 EVD outbreaks since the discovery of EBOV in 1976 [1] . From 2013 to 2016, the largest EVD outbreak occurred in Western Africa (mainly Guinea, Liberia, and Sierra Leone), with 28,652 cases and 11, 325 deaths [2, 3] . The second-largest EVD outbreak occurred in Democratic Republic of the Congo from 2018 to 2020, with 3,481 reported cases and 2,299 deaths [4] . The high lethality associated with EVD (average �44% since 1976) underscores the need for effective medical countermeasures, such as vaccines and therapeutics, against EBOV. During and after 2013-2016 EVD outbreak, enormous progress was made in medical countermeasure development, resulting in United States (U.S.) Food and Drug Administration approval of the first vaccine, Ervebo, in December 2019 [5] . 

The 

6D8-PE38 RIT was expressed and purified, as described previously [19, 20] . Briefly, the RIT expression plasmid p6D8-PE38 was transformed into Max Efficiency DH5α Escherichia coli BL21(DE3) (New England Biolabs, Ipswich, MA, USA). Then, isopropyl-β-D-thiogalactopyranoside (IPTG, Millipore Sigma) was used to induce RIT expression. The inclusion body fraction was isolated from the bacterial pellets by lysozyme treatment and high-speed centrifugation (27,000 xg for 50 min at 4˚C). The RIT was denatured and solubilized in denaturing buffer (6 M guanidine HCl, 2 mM EDTA, 100 mM Tris-HCl, pH 8), followed by reduction of disulfide bonds by addition of dithioerythritol powder (Millipore Sigma) to achieve a 10-mg/ ml concentration, and incubation overnight at room temperature. The solubilized reduced RIT (MW = 66 kDa) was then refolded in refolding buffer (0.5 M arginine, 1 mM EDTA, 100 mM Tris-HCl, pH 9.5, 551 mg/ oxidized glutathione). The refolded proteins were dialyzed, and then purified by anion exchange chromatography using Q Sepharose and Mono Q anion exchangers (GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, USA) and size-exclusion chromatography on a TSK3000 column (Millipore Sigma). The purified RIT concentration was determined using a bicinchoninic acid (BCA) protein assay, according to the manufacturer's instructions (Thermo Fisher Scientific). The protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie blue solution (SimplyBlue Safe Stain, Thermo Fisher Scientific).

Vero E6 cells (4 x 10 5 cells/well, 6-well plate format) were transiently transfected with 2.5 μg of empty or EBOV (variant Yambuku, isolate Mayinga) GP 1,2 or Marburg virus (MARV, variant Mt. Elgon, isolate Musoke) GP 1,2 pCAGGS expression plasmids [21, 22] using Roche X-treme-GENE HP DNA transfection reagent (Millipore Sigma). Cells were dissociated with enzymefree cell-dissociation buffer (Thermo Fisher Scientific) 48 h post-transfection (p.t.) and stained with 2 μg/ml of mAb 6D8, followed by Alexa Fluor 488-conjugated goat anti-mouse immunoglobulin G (IgG) antibody (Thermo Fisher Scientific) on ice. As a control, all cells were stained with the same concentration of mouse IgG, followed by the same secondary antibody. These samples were analyzed with an LSRFortessa flow cytometer (Becton, Dickinson and Company, San Jose, CA, USA), and the data were analyzed with FlowJo software (Tree Star, Ashland, Oregon, USA). All experiments were performed in duplicates.

6D8-PE38 RIT was labeled with an Alexa Fluor 488 microscale protein labeling kit, according to the manufacturer's instructions (Thermo Fisher Scientific). Vero E6 cells were transiently transfected with pCAGGS-EBOV-GP 1,2 or control pCAGGS-MARV-GP 1,2 . 48 h p.t., cells were dissociated with enzyme-free cell-dissociation buffer. Transfected cells were washed with phosphate-buffered saline (Thermo Fisher Scientific) and then incubated with phosphate-buffered saline containing 3% bovine serum albumin (Millipore Sigma) at 4˚C for 30 min to block non-specific binding. The cells were then incubated with different concentrations of labeled 6D8-PE38 RIT at 4˚C for 1 h. The binding of immunotoxin on the cell surface was analyzed by flow cytometry. All experiments were performed in duplicates.

Huh-7 cells (4 x 10 4 cells/well, 96-well plate format) or MDMs (1 x 10 5 cells/well, 96-well plate format) were inoculated with EBOV at an MOI of 0.3 or 3. After 1 h of incubation at 37˚C, viral inoculums were removed, and the cells were supplemented with DMEM containing 2% FBS. At various times post-inoculation, cell plates were fixed with 10% neutral buffered formalin (NBF, Thermo Fisher Scientific) for 24 h and then transferred from the BSL-4 to a BSL-2 laboratory. Without the permeabilization step, the plates were stained with mouse anti-EBOV GP 1,2 mAb 6D8, followed by secondary Alexa Fluor 488-conjugated goat anti-mouse IgG antibody (Thermo Fisher Scientific). Cell nuclei were stained with Hoechst 33342 dye (Thermo Fisher Scientific). Fluorescent signal images were acquired with the Operetta high-content imaging system (PerkinElmer, Waltham, MA, USA). All experiments were performed in duplicates. 

All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). Statistically significant differences in viral titer were determined by unpaired Student t-test ( � , P < 0.05, significant; �� , P < 0.01, very significant; ��� , P < 0.001, highly significant).

To test the potential and feasibility of the immunotoxin as a therapeutic concept, we chose mAb 6D8 to design an immunotoxin targeting EBOV GP 1,2 . Developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), mAb 6D8 is a non-neutralizing mAb that recognizes a linear epitope in the mucin-like domain of GP 1, 2 's GP 1 subunit (amino acid residues 389-405: HNTPVYKLDISEATQVE; absent in GP 1 s of other ebolaviruses and filoviruses) [23] . mAb 6D8 specifically bound to the cells transfected with an EBOV GP 1,2expressing plasmid but not to cells transfected with a MARV GP 1,2 -expressing plasmid or empty vector control plasmid (Fig 2) . An scFv of mAb 6D8, which contains the variable regions of the heavy and the light chains of mAb 6D8, connected by a 15-amino-acid linker (Gly 4 Ser) 3 , was linked to PE38, which contains only the translocation and effector domains of PE. We expressed this 6D8-PE38 RIT in Escherichia coli and purified it from the inclusion body fraction through standard protocols of solubilization, denaturation, refolding, ion exchange, and size-exclusion chromatography [24] . We detected the expression of the 6D8-PE38 RIT in bacterial culture upon IPTG induction and in the inclusion body fraction (Fig 3) . The size and purity of the 6D8-PE38 RIT (MW = 66 kDa) was demonstrated by SDS-PAGE and Coomassie staining (Fig 3) .

The specific binding of the 6D8-PE38 RIT to EBOV GP 1,2 , expressed on the cell surface, was evaluated by flow cytometry. As shown in Fig 4, 6D8-PE38 RIT bound to EBOV GP 1,2 , expressed on transfected Vero E6 cells in a dose-dependent manner. Moreover, the RIT did not bind to the control cells, demonstrating the binding specificity of 6D8-PE38 RIT.

To test the potential of the 6D8-PE38 RIT as a possible EBOV antiviral, we examined its effect on infectious virus production from cells infected with a wild-type EBOV Huh-7 cells or MDMs were exposed to live virus at an MOI of 0.3 or 3; mock-exposed cells served as negative controls. The expression of GP 1,2 at 8, 24, and 48 h p.e. was assessed by staining with mAb 6D8 (Fig 5) . GP 1,2 expression was observed in both virus-exposed cell types in an MOI-dependent and time-dependent fashion. At 8 h p.e., GP 1,2 expression was not detected in either cell type at either MOI; at 24 h p.e., GP 1,2 expression was evident in both cell types, with higher levels at MOI 3; and at 48 h p.e., GP 1,2 expression was robust in all cases. As expected, GP 1,2 expression could not be detected in mock-infected cells.

With the confirmation of efficient mAb 6D8 binding to cells infected with EBOV, we next tested whether the 6D8-PE38 RIT was active against the infected cells. We used suppression of EBOV release as a readout of infected cell killing, as previously used in human immunodeficiency virus 1 (HIV-1) infection studies [27] . Huh-7 cells or MDMs were infected with EBOV at an MOI of 0.3 or 3. At 1 h p.e., the infected cells were washed to remove unbound virions and then treated with increasing concentrations of 6D8-PE38 RIT or control YC15-PE38 RIT. The amount of produced infectious virions was quantitated by plaque assay. We observed a dose-dependent reduction of infectious EBOV production from both cell types by 6D8-PE38 RIT, but not by the unrelated control YC15-PE38 RIT, in both Huh-7 cells (Fig 6A) and MDMs (Fig 6B) . The observed potencies are comparable to reported data for other PE-based RITs with in vivo efficacy [28]. These effects cannot be explained by simple neutralization by the antibody component of the recombinant immunotoxin, since no reduction was observed with mAb 6D8 (Fig 6C) , consistent with a previous report demonstrating the non-neutralizing effects of this antibody [23] .

These data demonstrate the efficacy and specificity of the 6D8-PE38 RIT against EBOV infection.

The 2013-2016 EVD epidemic in Western Africa and recent outbreaks in the Democratic Republic of the Congo have highlighted the urgent need for effective antiviral therapeutics to meet future outbreaks. A number of investigational agents with promising activities in vitro and in animal models have been administered in the field and advanced to clinical studies [7, 29, 30] . Particularly promising are specific mAbs directed against EBOV GP 1,2 [31, 32], used singly (e.g., mAb114) or in combination (e.g., REGN-EB3 mAb cocktail); the therapeutic potential of these antibodies has been the focus of several clinical trials [7, 33, 34] .

This study is a first step toward an alternative EVD treatment strategy, using anti-EBOV antibodies for direct killing of virus target cells. Antibody-based target cell killing has been advanced in cancer treatment and is moving to the forefront of therapeutic approaches against diverse viral pathogens, including HIV-1. Specific efforts include adoptive transfer of T cells, e.g., natural virus-specific T cells expanded ex vivo [35] or genetically modified T cells expressing cloned T-cell receptors or chimeric antigen receptors [36, 37] ; another T-cell-mediated technology involves bispecific T-cell-engaging antibodies [38] . Distinct from these technically complex cell-mediated strategies, RIT technology typically involves intravenous infusion of a purified protein for direct killing of infected cells [39, 40] ; RITs targeting HIV-1 and other specific viral pathogens have been described [41] [42] [43] . We propose that immunotoxins, such as the 6D8-PE38 RIT reported herein, have potential therapeutic utility against EBOV. In this context, reported features of the original mAb 6D8 are noteworthy. This antibody strongly protected EBOV-exposed laboratory animals despite the absence of direct neutralizing activity; however, neutralization in the presence of complement was observed, suggesting that the in vivo protection reflected targeted killing of infected cells by either complement-mediated lysis or ADCC [23] . Indeed, Fc-mediated activities have been observed for many EBOV-protective antibodies [12, 44] , including components of leading therapeutic cocktails, such as REGN-EB3 MDMs were exposed to EBOV at the indicated MOIs. After 1 h, viral inoculums were removed, and the cells were treated with increasing concentrations of 6D8-PE38 RIT or control YC15-PE38 RIT. At 48 h post-exposure, tissue culture supernatants were collected, and virus titers were measured by plaque assay. Data represent the means ± the standard deviations of results from triplicate wells. � , P < 0.05; �� , P < 0.01; ��� , P < 0.001; ���� , P < 0.0001 (Student ttest). (C) Huh-7 cells were exposed to EBOV at the indicated MOIs. After 1 h, viral inocula were removed, and the cells were treated with increasing concentrations of mAb 6D8 or control mouse IgG. At 48 h post-exposure, tissue culture supernatants were collected, and virus titers were measured by plaque assay. Data represent the means ± the standard deviations of results from triplicate wells.

https://doi.org/10.1371/journal.pone.0245024.g006 [45] . RIT technology, which is based on replacing the Fc domain of an antibody with a cytotoxic protein moiety, offers a direct approach for targeted killing of EBOV-infected cells, and our results indicate the efficacy and specificity of such an RIT against EBOV infection. It should be noted that the observed suppressive activity of the 6d8-PE38 RIT cannot be explained by neutralization, since mAb 6D8 is a non-neutralization antibody [23] and because the 6D8-PE38 RIT was added 1 h p.e., after removal of excess virus. A significant advantage of the 6D8-PE38 RIT, compared to the original mAb 6D8, is that the required dosage to achieve efficacy likely will be orders of magnitude lower. The in vivo efficacy range for a PE-based RIT is typically 0.05 mg/kg or less per dose [46] , as contrasted with the 5-50 mg/kg range for mAb 6D8 [23] as well as other individual mAbs in efficacious anti-EBOV cocktails [7, 33, 34, 45, 47] . The mechanism of action of the 6D8-PE38 RIT tested here, which our data strongly suggest being preferential killing of EBOV-infected, will have to be evaluated further. Since EBOV, or over-expressed EBOV GP 1,2 , causes severe cytopathic effects in infected/transfected cells [48] [49] [50] , we could not separate these effects from cytopathic effects induced by the RIT. It is thus formally possible that the RIT exerted its EBOV-inhibitory effect by other or additional means, for instance via steric hindrance caused by the cytotoxic (here, PE38) moiety. Such alternative or additional actions may also contribute to off-target effects of the RIT on various cell types that will have to be defined.

Cell-culture studies have revealed synergistic activities between particular combinations of EBOV-inhibiting drugs [18] . In considering the RIT, relevance was based on previous cell-culture studies with HIV-1 that demonstrated robust synergy between one agent that inhibits virus replication and another that directly kills infected cells. For instance, combination treatment with an HIV-1 reverse transcriptase inhibitor (azidothymidine [AZT] or didanosine [DDI]) plus an RIT (CD4-PE40) completely eliminated HIV-1 from cultures, a result not approached with either agent alone [51] . Similar cooperative activities were observed in a humanized mouse model; combination treatment with HIV-1 replication blockers (reverse transcriptase and protease inhibitors) plus RIT CD4-PE40 nearly completely prevented virus rebound after cessation of treatment, in marked contrast with the limited effect of either class of agents alone [51] .

We hypothesize that RITs, similar to the proof-of-principle 6D8-PE38 RIT described here, will robustly complement EBOV-replication inhibitors. For example, an RIT might significantly enhance the therapeutic efficacy of a small-molecule RNA synthesis inhibitor, such as remdesivir, beyond what was observed clinically with remdesivir alone [7] . The molecular weights of mAbs and RITs are too large to pass through selectively permeable endothelial cell borders (e.g., blood-brain or blood-testis barriers). Hence, mAbs and RITs could only be used therapeutically to address acute EVD. However, in combination with EBOV-specific smallmolecule antivirals that cross such barriers, acute and persistent EBOV infection in immuneprivileged sites of EVD survivors [52] could be addressed simultaneously and synergistically [53] . In addition, recent studies suggest that RITs could be modified to enhance entry in privileged sites [54] . RITs could also be combined with anti-EBOV mAbs that act primarily by direct neutralization; these replication-blocking activities might be significantly complemented by the direct targeting cell-killing activity of the RIT. To achieve such a cooperative effect, mAb selection must avoid binding competition between the two antibody-based agents. mAb 6D8 binds to a linear epitope in the mucin-like domain of EBOV GP 1,2 [23, 55] , which is physically separate from the GP 1,2 core, base, and glycan cap that harbors the binding sites for the potent neutralizing mAbs of current therapeutic interest [12, 45, [55] [56] [57] . In recent years, numerous EBOV-specific mAbs have been described with a broad variety of properties [12] that could be taken into account for the development of EBOV-specific RITs with improved affinity and/or more preferable GP 1,2 -binding sites. In addition, mAbs could be chosen that bind the GP 1,2 s of multiple ebolaviruses (e.g., those of Bundibugyo virus [BDBV], Sudan virus [SUDV] , and/or Taï Forest virus [TAFV]), or even bind the GP 1,2 s of non-ebolavirus filoviruses, thereby resulting in broad-spectrum RITs.

Finally, we must consider general clinical concerns that have arisen during the extensive studies with anti-cancer RITs [39, 40] . The toxin moieties of clinically advanced RITs are generally derived from bacterial toxins. The immunogenicity of these nonhuman components has been a critical obstacle, prompting extensive de-immunization efforts through genetic modification [58] . This concern is minimized for EVD by the acute nature of the disease and the resulting short treatment window. Another obstacle for RIT therapy is the potential for doselimiting adverse effects, including on-target toxicity against normal cells expressing the same target molecule and off-target systemic toxicity, particularly vascular leak syndrome associated with toxin-induced damage to endothelial cells. On-target toxicity would likely be minimal for the 6D8-PE38 RIT, since surface expression of the target antigen is limited to EBOV-infected cells. The extent of off-target toxicity varies amongst different RITs, and can be reduced by specific genetic modifications of the toxin domain as has been reported for several PE-based RITs [59] [60] [61] . We hypothesize that none of these obstacles is insurmountable and that proofof-principle in vivo experiments ought to be performed to further evaluate the therapeutic potential of RITs against EVD. 

Ebola virus disease

World Health Organization. Ebola outbreak

A day-by-day chronicle of the 2013-2016 Ebola outbreak

World Health Organization. Ebola in the Democratic Republic of the Congo

First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response

Fields Virology. 1 (Emerging Viruses)

A randomized, controlled trial of Ebola virus disease therapeutics

Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

Ebola virus can be effectively neutralized by antibody produced in natural human infection

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail

Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection

Targeted diphtheria toxin-based therapy: a review article

Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia

Plant toxin-based immunotoxins for cancer therapy: a short overview

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

Virus-specific T cells: broadening applicability

T cell engineering as therapy for cancer and HIV: our synthetic future

Quarter century of anti-HIV CAR T cells

Bispecific antibodies: potential immunotherapies for HIV treatment

Advances in anticancer immunotoxin therapy

Critical issues in the development of immunotoxins for anticancer therapy

Biomedical Aspects of Drug Targeting

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

The future of antiviral immunotoxins

The structural basis for filovirus neutralization by monoclonal antibodies

Development of clinicalstage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo

Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry

Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence

Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors

Ebola virus persistence as a new focus in clinical research

Recent successes in therapeutics for Ebola virus disease: no time for complacency

Repurposing bacterial toxins for intracellular delivery of therapeutic proteins

Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies

Structures of protective antibodies reveal sites of vulnerability on Ebola virus

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Strategies to reduce the immunogenicity of recombinant immunotoxins

Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Characterization of a reengineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy